Rafferty Asset Management, LLC Apellis Pharmaceuticals, Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 204,146 shares of APLS stock, worth $6.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

204,146

Previous 241,982 15.64%

Holding current value

$6.8 Million

Previous $9.28 Million 36.58%

% of portfolio

0.02%

Previous 0.03%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$28.84 - $41.15 $1.09 Million - $1.56 Million	-37,836 Reduced 15.64%	204,146 $5.89 Million
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $3.55 Million - $5.56 Million	93,181 Added 62.62%	241,982 $9.28 Million
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $314,781 - $411,847	5,683 Added 3.97%	148,801 $8.75 Million
Q4 2023 Feb 13, 2024	SELL	$37.14 - $64.82 $2.64 Million - $4.61 Million	-71,043 Reduced 33.17%	143,118 $8.57 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $2.88 Million - $10.9 Million	121,893 Added 132.11%	214,161 $8.15 Million
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $1.31 Million - $1.6 Million	-17,130 Reduced 15.66%	92,268 $8.41 Million
Q1 2023 May 11, 2023	SELL	$46.59 - $66.96 $2.55 Million - $3.66 Million	-54,706 Reduced 33.34%	109,398 $7.22 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $2.66 Million - $3.76 Million	61,532 Added 59.99%	164,104 $8.49 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $433,411 - $674,517	9,683 Added 10.42%	102,572 $7.01 Million
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $1.07 Million - $1.81 Million	-30,606 Reduced 24.78%	92,889 $4.2 Million
Q1 2022 May 13, 2022	SELL	$35.46 - $54.12 $85,635 - $130,699	-2,415 Reduced 1.92%	123,495 $6.28 Million
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $1.13 Million - $1.8 Million	36,711 Added 41.16%	125,910 $5.95 Million
Q3 2021 Nov 10, 2021	BUY	$31.4 - $69.84 $1.48 Million - $3.3 Million	47,208 Added 112.42%	89,199 $2.94 Million
Q2 2021 Aug 10, 2021	SELL	$40.9 - $64.9 $1.2 Million - $1.91 Million	-29,421 Reduced 41.2%	41,991 $2.65 Million
Q1 2021 May 10, 2021	BUY	$40.8 - $57.39 $2.15 Million - $3.02 Million	52,653 Added 280.68%	71,412 $3.06 Million
Q4 2020 Feb 10, 2021	SELL	$30.79 - $57.2 $1.55 Million - $2.89 Million	-50,470 Reduced 72.9%	18,759 $1.07 Million
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $994,434 - $1.29 Million	38,410 Added 124.63%	69,229 $2.09 Million
Q2 2020 Aug 07, 2020	BUY	$24.8 - $38.49 $559,413 - $868,218	22,557 Added 273.02%	30,819 $1.01 Million
Q1 2020 May 15, 2020	SELL	$17.91 - $44.33 $1.11 Million - $2.75 Million	-61,996 Reduced 88.24%	8,262 $221,000
Q4 2019 Feb 10, 2020	BUY	$22.1 - $30.8 $233,795 - $325,833	10,579 Added 17.73%	70,258 $2.15 Million
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $123,437 - $164,890	-5,124 Reduced 7.91%	59,679 $1.44 Million
Q2 2019 Aug 09, 2019	BUY	$18.0 - $25.34 $674,100 - $948,983	37,450 Added 136.91%	64,803 $1.64 Million
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $350,391 - $542,136	27,353 New	27,353 $533,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.66B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Apellis Pharmaceuticals, Inc. Transaction History